Septerna appoints Keith Gottesdiener, M.D. to board as Class I director and R&D Committee chair

Septerna, Inc.

Appointment effective Sept 25; board expanded to eight; Gottesdiener serves three-year term until 2028.
Also appointed to Compensation Committee and as chair of newly constituted R&D Committee effective Sept 26.
Gottesdiener is independent under Nasdaq/SEC rules; no material transactions or family relationships with officers.
Compensation per standard non-employee director policy plus $12,000 annual retainer for R&D Committee chair.
Former CEO of Prime Medicine and Rhythm Pharmaceuticals; 16 years at Merck with over 20 drug approvals.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.